Teva said that previous trials of Huntexil showed significant symptomatic relief for patients with Huntington disease.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced that it has concluded an agreement with Denmark's NeuroSearch A/S (OMX: NEUR) to acquire all rights, assets and obligations relating to Huntexil (pridopidine / ACR16), a drug candidate being developed for the symptomatic treatment of hand movement, balance and gait disturbances in Huntington disease. Under the agreement, Teva will pay NeuroSearch $26 million over a period of at least six months. Teva added that regulatory and commercialization milestone payments may result in additional funding for NeuroSearch.